 | • レポートコード：MRC2Q12-16742 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、気管支拡張症治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 気管支拡張症治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 気管支拡張症治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 気管支拡張症治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの気管支拡張症治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の気管支拡張症治療薬の売上および2028年までの予測に焦点を当てています。 気管支拡張症治療薬のグローバル主要企業には、Grifols、GlaxoSmithKline、Sanofi、Boehringer-Ingelheim、Cadilapharma、Aradigm Corporation、Zambon、Santhera Pharmaceuticals、Bayer、Insmed Inc、Alitair Pharmaceuticals、Polyphor、Kamada Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 気管支拡張症治療薬市場は、タイプとアプリケーションによって区分されます。世界の気管支拡張症治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 硫酸アミカシン、ARD-3150、CHF-6333、塩酸シプロフロキサシン、ドキソフィリン、その他 【アプリケーション別セグメント】 オフライン薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 気管支拡張症治療薬製品概要 - タイプ別市場（硫酸アミカシン、ARD-3150、CHF-6333、塩酸シプロフロキサシン、ドキソフィリン、その他） - アプリケーション別市場（オフライン薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の気管支拡張症治療薬販売量予測2017-2028 - 世界の気管支拡張症治療薬売上予測2017-2028 - 気管支拡張症治療薬の地域別販売量 - 気管支拡張症治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別気管支拡張症治療薬販売量 - 主要メーカー別気管支拡張症治療薬売上 - 主要メーカー別気管支拡張症治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（硫酸アミカシン、ARD-3150、CHF-6333、塩酸シプロフロキサシン、ドキソフィリン、その他） - 気管支拡張症治療薬のタイプ別販売量 - 気管支拡張症治療薬のタイプ別売上 - 気管支拡張症治療薬のタイプ別価格 ・アプリケーション別市場規模（オフライン薬局、オンライン薬局） - 気管支拡張症治療薬のアプリケーション別販売量 - 気管支拡張症治療薬のアプリケーション別売上 - 気管支拡張症治療薬のアプリケーション別価格 ・北米市場 - 北米の気管支拡張症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の気管支拡張症治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの気管支拡張症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の気管支拡張症治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の気管支拡張症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の気管支拡張症治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の気管支拡張症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の気管支拡張症治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの気管支拡張症治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の気管支拡張症治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Grifols、GlaxoSmithKline、Sanofi、Boehringer-Ingelheim、Cadilapharma、Aradigm Corporation、Zambon、Santhera Pharmaceuticals、Bayer、Insmed Inc、Alitair Pharmaceuticals、Polyphor、Kamada Ltd ・産業チェーン及び販売チャネル分析 - 気管支拡張症治療薬の産業チェーン分析 - 気管支拡張症治療薬の原材料 - 気管支拡張症治療薬の生産プロセス - 気管支拡張症治療薬の販売及びマーケティング - 気管支拡張症治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 気管支拡張症治療薬の産業動向 - 気管支拡張症治療薬のマーケットドライバー - 気管支拡張症治療薬の課題 - 気管支拡張症治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Bronchiectasis Treatment Drug estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Bronchiectasis Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Bronchiectasis Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Bronchiectasis Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Bronchiectasis Treatment Drug include Grifols, GlaxoSmithKline, Sanofi, Boehringer-Ingelheim, Cadilapharma, Aradigm Corporation, Zambon, Santhera Pharmaceuticals and Bayer, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Bronchiectasis Treatment Drug companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Bronchiectasis Treatment Drug market. Further, it explains the major drivers and regional dynamics of the global Bronchiectasis Treatment Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Grifols
GlaxoSmithKline
Sanofi
Boehringer-Ingelheim
Cadilapharma
Aradigm Corporation
Zambon
Santhera Pharmaceuticals
Bayer
Insmed Inc
Alitair Pharmaceuticals
Polyphor
Kamada Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Bronchiectasis Treatment Drug Segment by Type
Amikacin Sulfate
ARD-3150
CHF-6333
Ciprofloxacin Hydrochloride
Doxofylline
Others
Bronchiectasis Treatment Drug Segment by Application
Offline Pharmacy
Online Pharmacy
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Bronchiectasis Treatment Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Bronchiectasis Treatment Drug market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Bronchiectasis Treatment Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Bronchiectasis Treatment Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Bronchiectasis Treatment Drug revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Bronchiectasis Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Bronchiectasis Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Grifols, GlaxoSmithKline, Sanofi, Boehringer-Ingelheim, Cadilapharma, Aradigm Corporation, Zambon, Santhera Pharmaceuticals and Bayer, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Bronchiectasis Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bronchiectasis Treatment Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bronchiectasis Treatment Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bronchiectasis Treatment Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Amikacin Sulfate
1.2.3 ARD-3150
1.2.4 CHF-6333
1.2.5 Ciprofloxacin Hydrochloride
1.2.6 Doxofylline
1.2.7 Others
1.3 Market by Application
1.3.1 Global Bronchiectasis Treatment Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Offline Pharmacy
1.3.3 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Bronchiectasis Treatment Drug Market Perspective (2017-2028)
2.2 Bronchiectasis Treatment Drug Growth Trends by Region
2.2.1 Bronchiectasis Treatment Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Bronchiectasis Treatment Drug Historic Market Size by Region (2017-2022)
2.2.3 Bronchiectasis Treatment Drug Forecasted Market Size by Region (2023-2028)
2.3 Bronchiectasis Treatment Drug Market Dynamics
2.3.1 Bronchiectasis Treatment Drug Industry Trends
2.3.2 Bronchiectasis Treatment Drug Market Drivers
2.3.3 Bronchiectasis Treatment Drug Market Challenges
2.3.4 Bronchiectasis Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bronchiectasis Treatment Drug Players by Revenue
3.1.1 Global Top Bronchiectasis Treatment Drug Players by Revenue (2017-2022)
3.1.2 Global Bronchiectasis Treatment Drug Revenue Market Share by Players (2017-2022)
3.2 Global Bronchiectasis Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bronchiectasis Treatment Drug Revenue
3.4 Global Bronchiectasis Treatment Drug Market Concentration Ratio
3.4.1 Global Bronchiectasis Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bronchiectasis Treatment Drug Revenue in 2021
3.5 Bronchiectasis Treatment Drug Key Players Head office and Area Served
3.6 Key Players Bronchiectasis Treatment Drug Product Solution and Service
3.7 Date of Enter into Bronchiectasis Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bronchiectasis Treatment Drug Breakdown Data by Type
4.1 Global Bronchiectasis Treatment Drug Historic Market Size by Type (2017-2022)
4.2 Global Bronchiectasis Treatment Drug Forecasted Market Size by Type (2023-2028)
5 Bronchiectasis Treatment Drug Breakdown Data by Application
5.1 Global Bronchiectasis Treatment Drug Historic Market Size by Application (2017-2022)
5.2 Global Bronchiectasis Treatment Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Bronchiectasis Treatment Drug Market Size (2017-2028)
6.2 North America Bronchiectasis Treatment Drug Market Size by Type
6.2.1 North America Bronchiectasis Treatment Drug Market Size by Type (2017-2022)
6.2.2 North America Bronchiectasis Treatment Drug Market Size by Type (2023-2028)
6.2.3 North America Bronchiectasis Treatment Drug Market Share by Type (2017-2028)
6.3 North America Bronchiectasis Treatment Drug Market Size by Application
6.3.1 North America Bronchiectasis Treatment Drug Market Size by Application (2017-2022)
6.3.2 North America Bronchiectasis Treatment Drug Market Size by Application (2023-2028)
6.3.3 North America Bronchiectasis Treatment Drug Market Share by Application (2017-2028)
6.4 North America Bronchiectasis Treatment Drug Market Size by Country
6.4.1 North America Bronchiectasis Treatment Drug Market Size by Country (2017-2022)
6.4.2 North America Bronchiectasis Treatment Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Bronchiectasis Treatment Drug Market Size (2017-2028)
7.2 Europe Bronchiectasis Treatment Drug Market Size by Type
7.2.1 Europe Bronchiectasis Treatment Drug Market Size by Type (2017-2022)
7.2.2 Europe Bronchiectasis Treatment Drug Market Size by Type (2023-2028)
7.2.3 Europe Bronchiectasis Treatment Drug Market Share by Type (2017-2028)
7.3 Europe Bronchiectasis Treatment Drug Market Size by Application
7.3.1 Europe Bronchiectasis Treatment Drug Market Size by Application (2017-2022)
7.3.2 Europe Bronchiectasis Treatment Drug Market Size by Application (2023-2028)
7.3.3 Europe Bronchiectasis Treatment Drug Market Share by Application (2017-2028)
7.4 Europe Bronchiectasis Treatment Drug Market Size by Country
7.4.1 Europe Bronchiectasis Treatment Drug Market Size by Country (2017-2022)
7.4.2 Europe Bronchiectasis Treatment Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bronchiectasis Treatment Drug Market Size (2017-2028)
8.2 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Type
8.2.1 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Bronchiectasis Treatment Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Application
8.3.1 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Bronchiectasis Treatment Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Region
8.4.1 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Bronchiectasis Treatment Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Bronchiectasis Treatment Drug Market Size (2017-2028)
9.2 Latin America Bronchiectasis Treatment Drug Market Size by Type
9.2.1 Latin America Bronchiectasis Treatment Drug Market Size by Type (2017-2022)
9.2.2 Latin America Bronchiectasis Treatment Drug Market Size by Type (2023-2028)
9.2.3 Latin America Bronchiectasis Treatment Drug Market Share by Type (2017-2028)
9.3 Latin America Bronchiectasis Treatment Drug Market Size by Application
9.3.1 Latin America Bronchiectasis Treatment Drug Market Size by Application (2017-2022)
9.3.2 Latin America Bronchiectasis Treatment Drug Market Size by Application (2023-2028)
9.3.3 Latin America Bronchiectasis Treatment Drug Market Share by Application (2017-2028)
9.4 Latin America Bronchiectasis Treatment Drug Market Size by Country
9.4.1 Latin America Bronchiectasis Treatment Drug Market Size by Country (2017-2022)
9.4.2 Latin America Bronchiectasis Treatment Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bronchiectasis Treatment Drug Market Size (2017-2028)
10.2 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Type
10.2.1 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Bronchiectasis Treatment Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Application
10.3.1 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Bronchiectasis Treatment Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Country
10.4.1 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Bronchiectasis Treatment Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Grifols
11.1.1 Grifols Company Details
11.1.2 Grifols Business Overview
11.1.3 Grifols Bronchiectasis Treatment Drug Introduction
11.1.4 Grifols Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.1.5 Grifols Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Bronchiectasis Treatment Drug Introduction
11.2.4 GlaxoSmithKline Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Bronchiectasis Treatment Drug Introduction
11.3.4 Sanofi Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.3.5 Sanofi Recent Developments
11.4 Boehringer-Ingelheim
11.4.1 Boehringer-Ingelheim Company Details
11.4.2 Boehringer-Ingelheim Business Overview
11.4.3 Boehringer-Ingelheim Bronchiectasis Treatment Drug Introduction
11.4.4 Boehringer-Ingelheim Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.4.5 Boehringer-Ingelheim Recent Developments
11.5 Cadilapharma
11.5.1 Cadilapharma Company Details
11.5.2 Cadilapharma Business Overview
11.5.3 Cadilapharma Bronchiectasis Treatment Drug Introduction
11.5.4 Cadilapharma Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.5.5 Cadilapharma Recent Developments
11.6 Aradigm Corporation
11.6.1 Aradigm Corporation Company Details
11.6.2 Aradigm Corporation Business Overview
11.6.3 Aradigm Corporation Bronchiectasis Treatment Drug Introduction
11.6.4 Aradigm Corporation Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.6.5 Aradigm Corporation Recent Developments
11.7 Zambon
11.7.1 Zambon Company Details
11.7.2 Zambon Business Overview
11.7.3 Zambon Bronchiectasis Treatment Drug Introduction
11.7.4 Zambon Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.7.5 Zambon Recent Developments
11.8 Santhera Pharmaceuticals
11.8.1 Santhera Pharmaceuticals Company Details
11.8.2 Santhera Pharmaceuticals Business Overview
11.8.3 Santhera Pharmaceuticals Bronchiectasis Treatment Drug Introduction
11.8.4 Santhera Pharmaceuticals Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.8.5 Santhera Pharmaceuticals Recent Developments
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Bronchiectasis Treatment Drug Introduction
11.9.4 Bayer Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.9.5 Bayer Recent Developments
11.10 Insmed Inc
11.10.1 Insmed Inc Company Details
11.10.2 Insmed Inc Business Overview
11.10.3 Insmed Inc Bronchiectasis Treatment Drug Introduction
11.10.4 Insmed Inc Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.10.5 Insmed Inc Recent Developments
11.11 Alitair Pharmaceuticals
11.11.1 Alitair Pharmaceuticals Company Details
11.11.2 Alitair Pharmaceuticals Business Overview
11.11.3 Alitair Pharmaceuticals Bronchiectasis Treatment Drug Introduction
11.11.4 Alitair Pharmaceuticals Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.11.5 Alitair Pharmaceuticals Recent Developments
11.12 Polyphor
11.12.1 Polyphor Company Details
11.12.2 Polyphor Business Overview
11.12.3 Polyphor Bronchiectasis Treatment Drug Introduction
11.12.4 Polyphor Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.12.5 Polyphor Recent Developments
11.13 Kamada Ltd
11.13.1 Kamada Ltd Company Details
11.13.2 Kamada Ltd Business Overview
11.13.3 Kamada Ltd Bronchiectasis Treatment Drug Introduction
11.13.4 Kamada Ltd Revenue in Bronchiectasis Treatment Drug Business (2017-2022)
11.13.5 Kamada Ltd Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer